⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Butane SCHEMBL583590 | 0.89 | — | — | |
| Ethyl Chloride SCHEMBL1818082 | 0.89 | — | — | |
| Alcohol SCHEMBL9644499 | 0.86 | — | — | |
| Chloromethane SCHEMBL1814391 | 0.84 | — | — | |
| Ethane SCHEMBL108080 | 0.84 | — | — | |
| SCHEMBL4743209 | 0.83 | — | — | |
| SCHEMBL102156 | 0.83 | — | — | |
| Pentane SCHEMBL583306 | 0.83 | — | — | |
| SCHEMBL5078402 | 0.80 | — | — | |
| Methane SCHEMBL204080 | 0.79 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170342089-A1 | NOVEL COMPOUNDS AS MODULATORS OF GPR-119 | RHIZEN PHARMACEUTICALS SA (CH) | 2017-11-30 | — | — | US | disclosed |
| US-9777018-B2 | Compounds as modulators of GPR-119 | RHIZEN PHARMACEUTICALS SA (CH) | 2017-10-03 | — | — | US | disclosed |
| EP-2718279-B1 | NOVEL COMPOUNDS AS MODULATORS OF GPR-119 | RHIZEN PHARMACEUTICALS SA (CH) | 2016-08-10 | — | — | EP | disclosed |
| US-20150361092-A1 | NOVEL COMPOUNDS AS MODULATORS OF GPR-119 | RHIZEN PHARMACEUTICALS SA (CH) | 2015-12-17 | — | — | US | disclosed |
| US-9181214-B2 | Bicyclic compounds as modulators of GPR-119 | RHIZEN PHARMACEUTICALS SA (CH) | 2015-11-10 | — | — | US | disclosed |
| EP-2718279-A1 | NOVEL COMPOUNDS AS MODULATORS OF GPR-119 | Rhizen Pharmaceuticals S.A. (CH) | 2014-04-16 | — | — | EP | disclosed |
| US-20130045986-A1 | NOVEL COMPOUNDS AS MODULATORS OF GPR-119 | RHIZEN PHARMACEUTICALS SA (CH) | 2013-02-21 | — | — | US | disclosed |
| WO-2012170867-A1 | NOVEL COMPOUNDS AS MODULATORS OF GPR-119 | RHIZEN PHARMACEUTICALS SA (CH) | 2012-12-13 | — | — | WO | disclosed |
| EP-2496270-A1 | ZIRCONIUM-RADIOLABELED, CYSTEINE ENGINEERED ANTIBODY CONJUGATES | F. Hoffmann-La Roche AG (CH) | 2012-09-12 | — | — | EP | disclosed |
| EP-2480529-A1 | INDOLE DERIVATIVES AS CRAC MODULATORS | F. Hoffmann-La Roche AG (CH) | 2012-08-01 | — | — | EP | disclosed |
| WO-2008141976-A1 | DIACYLGLYCEROL ACYLTRANSFERASE INHIBITORS | VIA PHARMACEUTICALS, INC. (US) | 2008-11-27 | — | — | WO | disclosed |
| WO-2008137436-A1 | [6,5]-BICYCLIC GPR119 G PROTEIN-COUPLED RECEPTOR AGONISTS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-11-13 | — | — | WO | disclosed |
| EP-1984332-A2 | METHODS FOR TREATING HEPATITIS C | PTC Therapeutics, Inc. (US) | 2008-10-29 | — | — | EP | disclosed |
| WO-2008100805-A2 | ANTI-ROBO4 ANTIBODIES AND USES THEREFOR | GENENTECH, INC. (US) | 2008-08-21 | — | — | WO | disclosed |
| WO-2007146695-A1 | ACYCLIC OXIMYL HEPATITIS C PROTEASE INHIBITORS | ENANTA PHARMACEUTICALS, INC. (US) | 2007-12-21 | — | — | WO | disclosed |
| WO-2007084413-A2 | METHODS FOR TREATING HEPATITIS C | PTC THERAPEUTICS, INC. (US) | 2007-07-26 | — | — | WO | disclosed |
| WO-2005000311-A1 | SUBSTITUTED DIKETOPIPERAZINES FOR THE TREATMENT OF BENIGN PROSTATIC HYPERPLASIA | GLAXO GROUP LIMITED (GB) | 2005-01-06 | — | — | WO | disclosed |
| EP-1093368-A4 | INDOLE AND TETRAHYDROISOQUINOLINE CONTAINING $g(a)-KETO OXADIAZOLES AS SERINE PROTEASE INHIBITORS | CORTECH INC (US) | 2002-11-13 | — | — | EP | disclosed |
| EP-1093368-A1 | INDOLE AND TETRAHYDROISOQUINOLINE CONTAINING $g(a)-KETO OXADIAZOLES AS SERINE PROTEASE INHIBITORS | Cortech Inc. (US) | 2001-04-25 | — | — | EP | disclosed |
| WO-1999062514-A1 | INDOLE AND TETRAHYDROISOQUINOLINE CONTAINING α-KETO OXADIAZOLES AS SERINE PROTEASE INHIBITORS | CORTECH INC. (US) | 1999-12-09 | — | — | WO | disclosed |